Tumor lymphatics

Seminars in Cancer Biology

Volumn 19, Issue 5, 2009, Pages 285-297

  Sleeman, Jonathan ^a,b   Schmid, Anja ^b   Thiele, Wilko ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Lymph node; Lymphangiogenesis; Lymphatic endothelial cells; Metastasis; Tumor dissemination; VEGF C; VEGF D; VEGFR 3

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; ANGIOTENSIN I; APRICOXIB; AXITINIB; BEVACIZUMAB; CCRIS 8679; CCRIS 9076; CD4 ANTIGEN; CD8 ANTIGEN; CEDIRANIB; CELECOXIB; CYCLOOXYGENASE 2; CYTOKINE; ETODOLAC; HSDB 7038; IMATINIB; MONOCLONAL ANTIBODY DC101; MOTESANIB; NAPROXEN; NILOTINIB; NITRIC OXIDE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR BB; SCATTER FACTOR; SEMAXANIB; SEMAXINIB; SORAFENIB; SUNITINIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; VATALANIB; XL 647;

AXILLARY LYMPH NODE; BREAST CANCER; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FATE; CLINICAL OBSERVATION; CLINICAL TRIAL; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG EFFICACY; ENDOTHELIUM CELL; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; MALIGNANT NEOPLASTIC DISEASE; MASTECTOMY; MEDICAL RESEARCH; METASTASIS POTENTIAL; NONHUMAN; PROGNOSIS; REVIEW; SENTINEL LYMPH NODE; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNOLOGY;

HUMANS; LYMPHANGIOGENESIS; LYMPHATIC VESSELS; NEOPLASMS;

EID: 70549085152     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2009.05.005     Document Type: Review

References (183)

1. Guyton A., and Hall J. Textbook of medical physiology. 9th ed. (1996), W.B. Saunders Company, Philadelphia
2. Jain R.K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 81 (1989) 570-576
3. Sleeman J.P. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res 157 (2000) 55-81
4. Beahrs O., and Myers M. Purpose and principles of staging. In: Beahrs O., and Myers M. (Eds). Manual for staging of cancer (1983), Lippincott, Philadelphia 3-5
5. Leong S.P., Cady B., Jablons D.M., Garcia-Aguilar J., Reintgen D., Jakub J., et al. Clinical patterns of metastasis. Cancer Metastasis Rev 25 (2006) 221-232
6. Chikly B. Who discovered the lymphatic system?. Lymphology 30 (1997) 186-193
7. Weiss L. Metastasis of cancer: a conceptual history from antiquity to the 1990s. Cancer Metastasis Rev 19 (2000) 193-383
8. Peyrilhe B. Dissertatio academica De cancro. Antwerp; 1775.
9. Leake J. Medical instructions towards the prevention and cure of chronic and slow diseases peculiar to women (1777), Baldwin R and Murray A, London
10. Baille M. The morbid anatomy of some of the most important parts of the human body (1793), Johnson & Nicol, London
11. Cheselden W. The operations in surgery of Mons. LeDran. 1st ed. (1749), Hitch and Dosley, London
12. Buchan W. Domestic medicine. 1st ed. (1769), Balfour, Auld and Smellie, Edinburgh
13. Virchow R. Die krankhaften Geschwülste. 1st ed. (1863), August Hirschwald, Berlin
14. Virchow R. Die Cellularpathologie in ihrer Begründung auf physiologische und pathologische Gewebelehre. 1st ed. (1858), August Hirschwald, Berlin
15. Heidenhain L. Über die Ursachen der localen Krebsrecidive nach Amputio mammae. Arch Klein Chir 39 (1889) 71-97
16. Stiles H.J. On the dissemination of cancer of the breast. Br Med J 1 (1899) 1452-1459
17. Willis R. The spread of tumors in the human body. 3rd ed. (1973), Butterworth, London
18. Arnaout-Alkarain A., Kahn H.J., Narod S.A., Sun P.A., and Marks A.N. Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 20 (2007) 183-191
19. Leu A.J., Berk D.A., Lymboussaki A., Alitalo K., and Jain R.K. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 60 (2000) 4324-4327
20. Von Recklinghausen F. Ueber die venöse Embolie und den retrograden Transport in den Venen und in den Lymphgefässen. Virchows Arch Path Anat Physiol 100 (1885) 503-539
21. Vogel L. Über die Bedeutung der retrograden Metastasen innerhalb der Lymphbahn für die Kenntnis des Lymphgefäßsystems der parenchymatösen Organe. Virchows Arch Path Anat Physiol 125 (1891) 495-519
22. Vierth K. Über rückläufige Metastasen in den Lymphbahnen. Beitr Pathol Anat 18 (1895) 515-533
23. Gould E.A., Winship T., Philbin P.H., and Kerr H.H. Observations on a "sentinel node" in cancer of the parotid. Cancer 13 (1960) 77-78
24. Cabanas R.M. An approach for the treatment of penile carcinoma. Cancer 39 (1977) 456-466
25. Tanis P.J., Nieweg O.E., Valdés Olmos R.A., Th Rutgers E.J., and Kroon B.B. History of sentinel node and validation of the technique. Breast Cancer Res 3 (2001) 109-112
26. Sappey MPC. Anatomie, physiologie pathologie des vaisseaux lymphatiques considerées chez l'homme et les vertébres (1874), A. Delahaye & E. Lacrosnier, Paris
27. Sugarbaker P.H. Carcinoma of the colon-prognosis and operative choice. Curr Probl Surg 18 (1981) 753-802
28. Birch-Hirschfeld F.V. Lehrbuch der pathologischen Anatomie. Band 1 allgemeine pathologische Anatomie. 3rd ed. (1886), FCW Vogel, Leipzig
29. Birch-Hirschfeld F.V. Lehrbuch der pathologischen Anatomie. Band 2 specielle pathologische Anatomie. 3rd ed. (1887), FCW Vogel, Leipzig
30. Goldman E.E. Relation of cancer cells to blood vessels and ducts. Lancet 1 (1906) 23
31. Ewing J. Neoplastic diseases: a treatise on tumors. 3rd ed. (1928), Saunders, Philadelphia
32. Moynihan G. The surgical treatment of cancer of the sigmoid flexure and rectum. Surg Gynecol Obstet 6 (1908) 463-466
33. Crile Jr. G., Isbister W., and Deodhar S.D. Demonstration that large metastases in lymph nodes disseminate cancer cells to blood and lungs. Cancer 28 (1971) 657
34. Ward P.M., and Weiss L. Metachronous seeding of lymph node metastases in rats bearing the MT-100-TC mammary carcinoma: the effect of elective lymph node dissection. Breast Cancer Res Treat 14 (1989) 315-320
35. Paget S. The distribution of secondary growths in cancer of the breast. Lancet (1889) 571-573
36. Harris J., Morrow M., and Bonadonna G. Cancer of the breast. In: Devita V., Hellman S., and Rosenberg S.J.B. (Eds). Cancer, principles and practice of oncology. 4th ed. (1993), Lippincott Company, Philadelphia 1264-1332
37. Veronesi U. NIH consensus meeting on early breast cancer. Eur J Cancer 26 (1990) 843-844
38. Cady B. Regional lymph node metastases; a singular manifestation of the process of clinical metastases in cancer: contemporary animal research and clinical reports suggest unifying concepts. Ann Surg Oncol 14 (2007) 1790-1800
39. Terrone C., Cracco C., Porpiglia F., Bollito E., Scoffone C., Poggio M., et al. Reassessing the current TNM lymph node staging for renal cell carcinoma. Eur Urol 49 (2006) 324-331
40. Blazer III D.G., Sabel M.S., and Sondak V.K. Is there a role for sentinel lymph node biopsy in the management of sarcoma?. Surg Oncol 12 (2003) 201-206
41. Koch F.E. Zur Frage der Metastasenbildung bei Impftumoren. Z Krebsforsch 48 (1939) 495-497
42. Nicolson G.L. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7 (1988) 143-188
43. Eccles S., Paon L., and Sleeman J. Lymphatic metastasis in breast cancer: importance and new insights into cellular and molecular mechanisms. Clin Exp Metastasis 24 (2007) 619-636
44. Müller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 410 (2001) 50-56
45. Arya M., Patel H.R., McGurk C., Tatoud R., Klocker H., Masters J., et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 4 (2004) 291-293
46. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 18 (2004) 1240-1242
47. Wiley H.E., Gonzalez E.B., Maki W., Wu M.T., and Hwang S.T. Expression of CC chemokine receptor-7 and regional lymph node metastasis of B16 murine melanoma. J Natl Cancer Inst 93 (2001) 1638-1643
48. Shields J.D., Emmett M.S., Dunn D.B., Joory K.D., Sage L.M., Rigby H., et al. Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 26 (2007) 2997-3005
49. Fisher B., and Fisher E.R. Transmigration of lymph nodes by tumor cells. Science 152 (1966) 1397-1398
50. Fisher B., and Fisher E.R. The interrelationship of hematogenous and lymphatic tumor cell dissemination. Surg Gynecol Obstet 122 (1966) 791-798
51. Fisher B., and Fisher E.R. Significance of the interrelationship of the lymph and blood vascular systems in tumor cell dissemination. Prog Clin Cancer 4 (1970) 84-96
52. Fisher B., and Fisher E.R. The organ distribution of disseminated 51 Cr-labeled tumor cells. Cancer Res 27 (1967) 412-420
53. Heiss M.M., Allgayer H., Gruetzner K.U., Funke I., Babic R., Jauch K.W., et al. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer. Nat Med 1 (1995) 1035-1039
54. Klein C.A. The direct molecular analysis of metastatic precursor cells in breast cancer: a chance for a better understanding of metastasis and for personalised medicine. Eur J Cancer 44 (2008) 2721-2725
55. Gilchrist R.K. Fundamental factors governing lymphatic spread of carcinoma. Ann Surg 111 (1940) 630-639
56. Zeidman I., and Buss J.M. Experimental studies on the spread of cancer in the lymphatic system. I. Effectiveness of the lymph node as a barrier to the passage of embolic tumor cells. Cancer Res 8 (1954) 123-127
57. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg 119 (1984) 1067-1072
58. Haigh P.I., Lucci A., Turner R.R., Bostick P.J., Krasne D.L., Stern S.L., et al. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 92 (2001) 535-541
59. Gervasoni Jr. J.E., Taneja C., Chung M.A., and Cady B. Biologic and clinical significance of lymphadenectomy. Surg Clin North Am 80 (2000) 1631-1673
60. Madden R.E., and Gyure L. Translymphnodal passage of tumor cells. Oncology 22 (1968) 281-289
61. Kurokawa Y. Experiments on lymph node metastasis by intralymphatic inoculation of rat ascites tumor cells, with special reference to lodgement, passage, and growth of tumor cells in lymph nodes. Gann 61 (1970) 461-471
62. Carr J., Carr I., Dreher B., and Betts K. Lymphatic metastasis: invasion of lymphatic vessels and efflux of tumour cells in the afferent popliteal lymph as seen in the Walker rat carcinoma. J Pathol 132 (1980) 287-295
63. Grundmann E., and Vollmer E. Early local reaction and lymph node permeation of rat carcinoma HH9-cl 14 cells. An immunohistological approach. Pathol Res Pract 179 (1985) 304-309
64. Hewitt H.B., and Blake E. Quantitative studies of translymphnodal passage of tumour cells naturally disseminated from a non immunogenic murine squamous carcinoma. Br J Cancer 31 (1975) 25-35
65. Ludwig J., and Titus J.L. Experimental tumor cell emboli in lymph nodes. Arch Pathol 84 (1967) 304-311
66. Fidler I.J., Gersten D.M., and Riggs C.W. Relationship of host immune status to tumor cell arrest, distribution, and survival in experimental metastasis. Cancer 40 (1977) 46-55
67. Tachibana T., and Yoshida K. Role of the regional lymph node in cancer metastasis. Cancer Metastasis Rev 5 (1986) 55-66
68. Cochran A.J., Huang R.R., Lee J., Itakura E., Leong S.P., and Essner R. Tumour-induced immune modulation of sentinel lymph nodes. Nat Rev Immunol 6 (2006) 659-670
69. Cochran A.J., Wen D.R., Farzad Z., Stene M.A., McBride W., Lana A.M., et al. Immunosuppression by melanoma cells as a factor in the generation of metastatic disease. Anticancer Res 9 (1989) 859-864
70. Reiss C.K., Volenec F.J., Humphrey M., Singla O., and Humphrey L.J. The role of the regional lymph node in breast cancer: a comparison between nodal and systemic reactivity. J Surg Oncol 22 (1983) 249-253
71. Huang R.R., Wen D.R., Guo J., Giuliano A.E., Nguyen M., Offodile R., et al. Selective modulation of paracortical dendritic cells and T-lymphocytes in breast cancer sentinel lymph nodes. Breast J 6 (2000) 225-232
72. Kohrt H.E., Nouri N., Nowels K., Johnson D., Holmes S., and Lee P.P. Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med 2 (2005) e284
73. Preynat-Seauve O., Contassot E., Schuler P., Piguet V., French L.E., and Huard B. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Cancer Res 67 (2007) 5009-5016
74. Kim R., Emi M., Tanabe K., and Arihiro K. Immunobiology of the sentinel lymph node and its potential role for antitumour immunity. Lancet Oncol 7 (2006) 1006-1016
75. Fisher B., Redmond C., and Fisher E.R. The contribution of recent NSABP clinical trials of primary breast cancer therapy to an understanding of tumor biology-an overview of findings. Cancer 46 (1980) 1009-1025
76. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure: the David A. Karnofsky memorial lecture. Cancer Res 40 (1980) 3863-3874
77. Meyer K.K., and Beck W.C. Mastectomy performed by Lawrence Heister in the eighteenth century. Surg Gynecol Obstet 159 (1984) 391-394
78. Halsted W.S. Operations for carcinoma of the breast. Johns Hopkins Hosp Reports 2 (1891) 277-280
79. Halsted W.S. The results of operations for the cure of cancer of the breast performed at the Johns Hopkins Hospital from June, 1889, to January, 1894. Ann Surg 20 (1894) 497-555
80. Halsted W.S. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 46 (1907) 1-19
81. Pharis D.B., and Zitelli J.A. The management of regional lymph nodes in cancer. Br J Dermatol 149 (2003) 919-925
82. Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1995;333:1444-55.
83. Veronesi U., Marubini E., Mariani L., Valagussa P., and Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-Year results of a randomised trial. Eur J Cancer 35 (1999) 1320-1325
84. Thiele W., and Sleeman J.P. Tumor-induced lymphangiogenesis: a target for cancer therapy?. J Biotechnol 124 (2006) 224-241
85. Aprelikova O., Pajusola K., Partanen J., Armstrong E., Alitalo R., Bailey S.K., et al. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter. Cancer Res 52 (1992) 746-748
86. Kaipainen A., Korhonen J., Mustonen T., van Hinsbergh V.W., Fang G.H., Dumont D., et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development. Proc Natl Acad Sci USA 92 (1995) 3566-3570
87. Kukk E., Lymboussaki A., Taira S., Kaipainen A., Jeltsch M., Joukov V., et al. VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development. Development 122 (1996) 3829-3837
88. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95 (1998) 548-553
89. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., et al. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15 (1996) 290-298
90. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 (1997) 1423-1425
91. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E., Weich H.A., Christ B., et al. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev Biol 188 (1997) 96-109
92. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., Petrova T.V., et al. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 20 (2001) 1223-1231
93. He Y., Karpanen T., and Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 1654 (2004) 3-12
94. Achen M.G., and Stacker S.A. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer 119 (2006) 1755-1760
95. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 20 (2001) 672-682
96. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., et al. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 7 (2001) 192-198
97. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7 (2001) 186-191
98. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 94 (2002) 819-825
99. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S., et al. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res 63 (2003) 713-722
100. Hirakawa S., Brown L.F., Kodama S., Paavonen K., Alitalo K., and Detmar M. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 109 (2007) 1010-1017
101. Kopfstein L., Veikkola T., Djonov V.G., Baeriswyl V., Schomber T., Strittmatter K., et al. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am J Pathol 170 (2007) 1348-1361
102. Matsui J., Funahashi Y., Uenaka T., Watanabe T., Tsuruoka A., and Asada M. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 14 (2008) 5459-5465
103. Burton J.B., Priceman S.J., Sung J.L., Brakenhielm E., An D.S., Pytowski B., et al. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 68 (2008) 7828-7837
104. Sleeman J.P., Krishnan J., Kirkin V., and Baumann P. Markers for the lymphatic endothelium: in search of the holy grail?. Microsc Res Tech 55 (2001) 61-69
105. Wirzenius M., Tammela T., Uutela M., He Y., Odorisio T., Zambruno G., et al. Distinct vascular endothelial growth factor signals for lymphatic vessel enlargement and sprouting. J Exp Med 204 (2007) 1431-1440
106. Breiteneder-Geleff S., Soleiman A., Kowalski H., Horvat R., Amann G., Kriehuber E., et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154 (1999) 385-394
107. Banerji S., Ni J., Wang S.X., Clasper S., Su J., Tammi R., et al. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell Biol 144 (1999) 789-801
108. Wigle J.T., and Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 98 (1999) 769-778
109. Valtola R., Salven P., Heikkilä P., Taipale J., Joensuu H., Rehn M., et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 154 (1999) 1381-1390
110. Kubo H., Fujiwara T., Jussila L., Hashi H., Ogawa M., Shimizu K., et al. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96 (2000) 546-553
111. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., and Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am J Pathol 156 (2000) 1499-1504
112. Clarijs R., Schalkwijk L., Hofmann U.B., Ruiter D.J., and de Waal R.M. Induction of vascular endothelial growth factor receptor-3 expression on tumor microvasculature as a new progression marker in human cutaneous melanoma. Cancer Res 62 (2002) 7059-7065
113. Tammela T., Zarkada G., Wallgard E., Murtomäki A., Suchting S., Wirzenius M., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 454 (2008) 656-660
114. Su J.L., Yen C.J., Chen P.S., Chuang S.E., Hong C.C., Kuo I.H., et al. The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 96 (2007) 541-545
115. Petrova T.V., Bono P., Holnthoner W., Chesnes J., Pytowski B., Sihto H., et al. VEGFR-3 expression is restricted to blood and lymphatic vessels in solid tumors. Cancer Cell 13 (2008) 554-556
116. Schledzewski K., Falkowski M., Moldenhauer G., Metharom P., Kzhyshkowska J., Ganss R., et al. Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. J Pathol 209 (2006) 67-77
117. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 115 (2005) 2363-2372
118. Wróbel T., Dziegiel P., Mazur G., Zabel M., Kuliczkowski K., and Szuba A. LYVE-1 expression on high endothelial venules (HEVs) of lymph nodes. Lymphology 38 (2005) 107-110
119. Schacht V., Dadras S.S., Johnson L.A., Jackson D.G., Hong Y.K., and Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166 (2005) 913-921
120. Wicki A., Lehembre F., Wick N., Hantusch B., Kerjaschki D., and Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9 (2006) 261-272
121. Kono T., Shimoda M., Takahashi M., Matsumoto K., Yoshimoto T., Mizutani M., et al. Immunohistochemical detection of the lymphatic marker podoplanin in diverse types of human cancer cells using a novel antibody. Int J Oncol 31 (2007) 501-508
122. Kawase A., Ishii G., Nagai K., Ito T., Nagano T., Murata Y., et al. Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123 (2008) 1053-1059
123. Veikkola T., Lohela M., Ikenberg K., Mäkinen T., Korff T., Saaristo A., et al. Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function. FASEB J 17 (2003) 2006-2013
124. Tammela T., Saaristo A., Holopainen T., Lyytikkä J., Kotronen A., Pitkonen M., et al. Therapeutic differentiation and maturation of lymphatic vessels after lymph node dissection and transplantation. Nat Med 13 (2007) 1458-1466
125. Kawai Y., Hosaka K., Kaidoh M., Minami T., Kodama T., and Ohhashi T. Heterogeneity in immunohistochemical, genomic, and biological properties of human lymphatic endothelial cells between initial and collecting lymph vessels. Lymphat Res Biol 6 (2008) 15-27
126. Sleeman JP, Thiele W. Tumor metastasis and the lymphatic vasculature. Int J Cancer 2009; in press.
127. Williams C.S., Leek R.D., Robson A.M., Banerji S., Prevo R., Harris A.L., et al. Absence of lymphangiogenesis and intratumoural lymph vessels in human metastatic breast cancer. J Pathol 200 (2003) 195-206
128. Agarwal B., Saxena R., Morimiya A., Mehrotra S., and Badve S. Lymphangiogenesis does not occur in breast cancer. Am J Surg Pathol 29 (2005) 1449-1455
129. Renyi-Vamos F., Tovari J., Fillinger J., Timar J., Paku S., Kenessey I., et al. Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer. Clin Cancer Res 11 (2005) 7344-7353
130. Liang P., Hong J.W., Ubukata H., Liu H.R., Watanabe Y., Katano M., et al. Increased density and diameter of lymphatic microvessels correlate with lymph node metastasis in early stage invasive colorectal carcinoma. Virchows Arch 448 (2006) 570-575
131. Van der Schaft D.W., Pauwels P., Hulsmans S., Zimmermann M., van de Poll-Franse L.V., and Griffioen A.W. Absence of lymphangiogenesis in ductal breast cancer at the primary tumor site. Cancer Lett 254 (2007) 128-136
132. Soares A.B., Ponchio L., Juliano P.B., de Araújo V.C., and Altemani A. Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma. J Clin Pathol 60 (2007) 995-1000
133. Baldewijns M.M., Roskams T., Ballet V., Van den Eynden G.G., Van Laere S.J., Van der Auwera I., et al. A low frequency of lymph node metastasis in clear-cell renal cell carcinoma is related to low lymphangiogenic activity. BJU Int (2009) [Epub ahead of print]
134. Da M.X., Wu Z., and Tian H.W. Tumor lymphangiogenesis and lymphangiogenic growth factors. Arch Med Res 39 (2008) 365-372
135. Cao R., Björndahl M.A., Religa P., Clasper S., Garvin S., Galter D., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6 (2004) 333-345
136. Iwata C., Kano M.R., Komuro A., Oka M., Kiyono K., Johansson E., et al. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 67 (2007) 10181-10189
137. Shibata M.A., Morimoto J., Shibata E., and Otsuki Y. Combination therapy with short interfering RNA vectors against VEGF-C and VEGF-A suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther 15 (2008) 776-786
138. Salven P., Mustjoki S., Alitalo R., Alitalo K., and Rafii S. VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 101 (2003) 168-172
139. Jiang S., Bailey A.S., Goldman D.C., Swain J.R., Wong M.H., Streeter P.R., et al. Hematopoietic stem cells contribute to lymphatic endothelium. PLoS ONE 3 (2008) e3812
140. Religa P., Cao R., Bjorndahl M., Zhou Z., Zhu Z., and Cao Y. Presence of bone marrow-derived circulating progenitor endothelial cells in the newly formed lymphatic vessels. Blood 106 (2005) 4184-4190
141. He Y., Rajantie I., Ilmonen M., Makinen T., Karkkainen M.J., Haiko P., et al. Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangiogenesis and lymphatic metastasis. Cancer Res 64 (2004) 3737-3740
142. Kerjaschki D., Huttary N., Raab I., Regele H., Bojarski-Nagy K., Bartel G., et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 12 (2006) 230-234
143. Conrad C., Niess H., Huss R., Huber S., von Luettichau I., Nelson P.J., et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation 119 (2009) 281-289
144. Mashino K., Sadanaga N., Yamaguchi H., Tanaka F., Ohta M., Shibuta K., et al. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res 62 (2002) 2937-2941
145. Shields J.D., Fleury M.E., Yong C., Tomei A.A., Randolph G.J., and Swartz M.A. Autologous chemotaxis as a mechanism of tumor cell homing to lymphatics via interstitial flow and autocrine CCR7 signaling. Cancer Cell 11 (2007) 526-538
146. Kaplan R.N., Rafii S., and Lyden D. Preparing the "soil": the premetastatic niche. Cancer Res 66 (2006) 11089-11093
147. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Brown L.F., and Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 201 (2005) 1089-1099
148. Harrell M.I., Iritani B.M., and Ruddell A. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Am J Pathol 170 (2007) 774-786
149. Ruddell A., Kelly-Spratt K.S., Furuya M., Parghi S.S., and Kemp C.J. p19/Arf and p53 suppress sentinel lymph node lymphangiogenesis and carcinoma metastasis. Oncogene 27 (2008) 3145-3155
150. Van den Eynden G.G., Van der Auwera I., Van Laere S.J., Huygelen V., Colpaert C.G., van Dam P., et al. Induction of lymphangiogenesis in and around axillary lymph node metastases of patients with breast cancer. Br J Cancer 95 (2006) 1362-1366
151. Sleeman J.P., and Cremers N. New concepts in breast cancer metastasis: tumor initiating cells and the microenvironment. Clin Exp Metastasis 24 (2007) 707-715
152. Matzkin H., Patel J.P., Altwein J.E., and Soloway M.S. Stage T1A carcinoma of prostate. Urology 43 (1994) 11-21
153. http://clinicaltrials.gov/ct2/home.
154. Barnes N.L., Warnberg F., Farnie G., White D., Jiang W., Anderson E., et al. Cyclooxygenase-2 inhibition: effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. Br J Cancer 96 (2007) 575-582
155. Schomber T., Zumsteg A., Strittmatter K., Crnic I., Antoniadis H., Littlewood-Evans A., et al. Differential effects of the vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 on tumor angiogenesis and tumor lymphangiogenesis. Mol Cancer Ther 8 (2009) 55-63
156. Heckman C.A., Holopainen T., Wirzenius M., Keskitalo S., Jeltsch M., Ylä-Herttuala S., et al. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res 68 (2008) 4754-4762
157. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Yang S., et al. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res 63 (2003) 5978-5991
158. Fischer C., Jonckx B., Mazzone M., Zacchigna S., Loges S., Pattarini L., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 131 (2007) 463-475
159. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., et al. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res 66 (2006) 2650-2657
160. Shimizu K., Kubo H., Yamaguchi K., Kawashima K., Ueda Y., Matsuo K., et al. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci 95 (2004) 328-333
161. Laakkonen P., Waltari M., Holopainen T., Takahashi T., Pytowski B., Steiner P., et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res 67 (2007) 593-599
162. Pytowski B., Goldman J., Persaud K., Wu Y., Witte L., Hicklin D.J., et al. Complete and specific inhibition of adult lymphatic regeneration by a novel VEGFR-3 neutralizing antibody. J Natl Cancer Inst 97 (2005) 14-21
163. Caunt M., Mak J., Liang W.C., Stawicki S., Pan Q., Tong R.K., et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 13 (2008) 331-342
164. Lin J., Lalani A.S., Harding T.C., Gonzalez M., Wu W.W., Luan B., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 65 (2005) 6901-6909
165. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., et al. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res 65 (2005) 4739-4746
166. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Ylä-Herttuala S., Jäättelä M., et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 61 (2001) 1786-1790
167. He X.W., Yu X., Liu T., Yu S.Y., and Chen D.J. Vector-based RNA interference against vascular endothelial growth factor-C inhibits tumor lymphangiogenesis and growth of colorectal cancer in vivo in mice. Chin Med J (Engl) 121 (2008) 439-444
168. Wang J., Zhang B., Guo Y., Li G., Xie Q., Zhu B., et al. Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C. Pharmacology 82 (2008) 148-155
169. Rothley M., Thiele W., Schacht V., Plaumann D., Gartner M., Giannis A., et al. Hyperforin and aristoforin inhibit lymphatic endothelial cell proliferation in vitro and suppress tumor-induced lymphangiogenesis in vivo. Int J Cancer 125 (2009) 34-42
170. Kobayashi S., Kishimoto T., Kamata S., Otsuka M., Miyazaki M., Ishikura H., et al. A specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98 (2007) 726-733
171. Brideau G., Mäkinen M.J., Elamaa H., Tu H., Nilsson G., Alitalo K., et al. Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 67 (2007) 11528-11535
172. Compagni A., Wilgenbus P., Impagnatiello M.A., Cotten M., and Christofori G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 60 (2000) 7163-7169
173. Casanovas O., Hicklin D.J., Bergers G., and Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8 (2005) 299-309
174. Su J.L., Yang P.C., Shih J.Y., Yang C.Y., Wei L.H., Hsieh C.Y., et al. The VEGF-C/Flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 9 (2006) 209-223
175. Saintigny P., Kambouchner M., Ly M., Gomes N., Sainte-Catherine O., Vassy R., et al. Vascular endothelial growth factor-C and its receptor VEGFR-3 in non-small-cell lung cancer: concurrent expression in cancer cells from primary tumour and metastatic lymph node. Lung Cancer 58 (2007) 205-213
176. Issa A., Le T.X., Shoushtari A.N., Shields J.D., and Swartz M.A. Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype. Cancer Res 69 (2009) 349-357
177. Rinderknecht M., and Detmar M. Tumor lymphangiogenesis and melanoma metastasis. J Cell Physiol 216 (2008) 347-354
178. Benest A.V., Harper S.J., Herttuala S.Y., Alitalo K., and Bates D.O. VEGF-C induced angiogenesis preferentially occurs at a distance from lymphangiogenesis. Cardiovasc Res 78 (2008) 315-323
179. Kaplan R.N., Riba R.D., Zacharoulis S., Bramley A.H., Vincent L., Costa C., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438 (2005) 820-827
180. Hiratsuka S., Watanabe A., Aburatani H., and Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8 (2006) 1369-1375
181. Hiratsuka S., Watanabe A., Sakurai Y., Akashi-Takamura S., Ishibashi S., Miyake K., et al. The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10 (2008) 1349-1355
182. Erler J.T., Bennewith K.L., Cox T.R., Lang G., Bird D., Koong A., et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15 (2009) 35-44
183. Pitchford S.C., Furze R.C., Jones C.P., Wengner A.M., and Rankin S.M. Differential mobilization of subsets of progenitor cells from the bone marrow. Cell Stem Cell 4 (2009) 62-72